NCT05140863

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week, Phase 3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Postherpetic Neuralgia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 372 (actual)
• Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Investigate the Efficacy and Safety of HSK16149 capsules in Chinese Postherpetic Neuralgia Following 12 Weeks Treatment in Comparison to Placebo

Conditions

• Postherpetic Neuralgia

Interventions

Type	Name	Description
DRUG	HSK16149 20mg BID	HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
DRUG	HSK16149 40mg BID	HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
DRUG	Placebo BID	Placebo, orally twice a day, treatment period; 12-weeks fixed dose

Timeline

• Start date: 2021-11-01
• Primary completion: 2022-12-22
• Completion: 2023-01-05
• First posted: 2021-12-02
• Last updated: 2023-02-27

Locations

2 sites across 1 country: China